KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Research & Development (2016 - 2025)

Jazz Pharmaceuticals has reported Research & Development over the past 16 years, most recently at $213.9 million for Q4 2025.

  • Quarterly Research & Development fell 11.06% to $213.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $842.6 million through Dec 2025, down 4.69% year-over-year, with the annual reading at $782.7 million for FY2025, 11.46% down from the prior year.
  • Research & Development was $213.9 million for Q4 2025 at Jazz Pharmaceuticals, up from $198.2 million in the prior quarter.
  • Over five years, Research & Development peaked at $240.5 million in Q4 2024 and troughed at $76.6 million in Q1 2021.
  • The 5-year median for Research & Development is $190.0 million (2025), against an average of $180.6 million.
  • Biggest five-year swings in Research & Development: skyrocketed 79.33% in 2021 and later fell 14.71% in 2024.
  • Tracing JAZZ's Research & Development over 5 years: stood at $155.4 million in 2021, then rose by 11.01% to $172.6 million in 2022, then grew by 25.53% to $216.6 million in 2023, then increased by 11.03% to $240.5 million in 2024, then fell by 11.06% to $213.9 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $213.9 million, $198.2 million, and $190.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.